Genmab's CEO pulls in DKK 37.3m salary – has shares worth DKK 1.6bn
Following an outstandingly profitable year for Genmab, CEO Jan van de Winkel got a pay raise, bringing his annual salary to DKK 37.3m. The CEO also owns a lucrative set of shares, which had a total market value of DKK 1.6bn at end-2020.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
This year, money has once again rained down on Genmab's Dutch Chief Executive Officer Jan van de Winkel, after 2020 proved to be an outstandingly profitable fiscal year for the company. Its revenue succeeded the predicted DKK 10.1bn (USD 1.65bn).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab CEO: Arbitration might be concluded in 2021
For subscribers
Genmab to take at least one new product to phase III in 2021
For subscribers
Genmab appoints chief medical officer
For subscribers
.jpg&w=384&q=75)
